Abstract 1937P
Background
The role of adjuvant chemotherapy for patients with a resected extremity soft tissue sarcoma (STS) is controversial. Prior individual patient data meta-analyses are limited by omission of certain randomized controlled trials. The objective of this systematic review was to reassess the efficacy of adjuvant chemotherapy in resected STS, harnessing the ability of a new method termed Kaplan Meier (KM) subtraction to obtain patient level information.
Methods
A comprehensive literature search was performed to identify RCTs of adjuvant chemotherapy for adult patients diagnosed with localized resectable soft-tissue sarcoma. We searched PubMed, Web of Science, Cochrane Controlled Trials Register, UKCCCR Register of Cancer Trials, Physicians Data Query, EMBASE, MEDLINE and CancerLit (until December 2022). Data on the following endpoints were evaluated: disease free survival (DFS) and overall survival (OS). Data were summarized as hazard ratios (HR) with 95% confidence intervals (CI). Two reviewers independently assessed eligibility and quality of the studies using a modified version of the Detsky Quality Scale. The outcome measures were disease free survival (DFS) and overall survival (OS) calculated through the fixed effect or random effect model. We applied KM subtraction in R to obtain individual patient level data from the trials for subsequent metanalysis.
Results
A total of 24 trials representing 5936 patients were be included in the final analysis. The disease-free survival hazard ratio was 1.76 (95% CI 1.38-2.24) in favour of adjuvant chemotherapy. The overall survival hazard ratio was 1.30 (95% CI 1.11-1.53) favouring adjuvant chemotherapy. For adjuvant chemotherapy with doxorubicin alone, the hazard ratio of DFS and OS were 1.78 (95% CI 1.10-2.88) and 1.47 (95% 1.01-2.13).
Conclusions
This is the largest individual patient meta-analysis to-date of adjuvant doxorubicin and ifosfamide based chemotherapy in localized resectable soft-tissue sarcoma, and confirms a survival benefit (particularly for single-agent doxorubicin) with respect to disease free survival and overall survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1960P - Clinical outcomes of the patients with alveolar soft part sarcoma developed brain metastasis
Presenter: Yu Toda
Session: Poster session 15
1961P - Prevalence of diagnostic discrepancies in soft tissue and bone tumors from initial diagnosis to referral center
Presenter: Khomsit Thongthammachat
Session: Poster session 15
1963P - Comprehensive profiling of chordoma reveals tumor microenvironment subtypes and unique molecular findings
Presenter: Marina Voropaeva
Session: Poster session 15
1964P - Biomimetics of three-dimensional (3D) osteosarcoma (OS) models: A scoping review
Presenter: Vinesh Sandhu
Session: Poster session 15
1965P - Transcriptional analysis of immune microenvironment of chordomas of the skull base and mobile spine
Presenter: Jason Roszik
Session: Poster session 15
1966P - Extending the interval of denosumab treatment for unresectable giant cell tumor of bone
Presenter: Toshiyuki Kunisada
Session: Poster session 15
1967P - A single-arm multicenter trial of the combination of anlotinib with chemotherapy in patients with stage IIb classic osteosarcoma of the extremity
Presenter: Fan Tang
Session: Poster session 15
1968P - Metastatic Ewing sarcoma, patterns of care and outcomes of patients in a real-life setting: The Metabone national observational study
Presenter: coline ducrot
Session: Poster session 15
1969P - Intratumoral immune infiltrates in chondrosarcoma (ChS)
Presenter: Piotr Rutkowski
Session: Poster session 15
1970P - Metastatic chondrosarcoma, patterns of care and outcomes of patients in a real-life setting: The Metabone national observational study
Presenter: coline ducrot
Session: Poster session 15